CLNN oral nanotherapeutic for ALS nears NDA submission
CLNN is advancing an oral nanotherapeutic for ALS, citing consistent neurofilament reduction and survival benefits in trials. The company says an NDA submission is imminent, with a confirmatory Phase III and targeted commercialization planned.
A clinical-stage biotech is advancing an oral nanotherapeutic for ALS, with trials showing consistent neurofilament reduction and survival benefits. The company said NDA submission is imminent, with a confirmatory phase III and targeted commercialization planned. It also cited a strong safety profile and pipeline potential in other indications.